Blueprint Medicines Corp to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics Inc Call Transcript
Good morning. My name is Juan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines Conference Call. (Operator Instructions)
I would like now to introduce to your host, Kristin Hodous from Blueprint. Kristin, please, you may begin your conference.
Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicines conference call to discuss our planned acquisition of Lengo Therapeutics. This morning, we issued a press release announcing the transaction, which we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing by going to the Investors section of our website, at www.blueprintmedicines.com.
Joining us today on our call are Jeff Albers, our Chief Executive Officer; Keith Haviland, our Chief Operating Officer; and Fouad Namouni, our President of Research and Development
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |